Literature DB >> 15626948

Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999-2000.

Tatiana M Lanzieri1, Maria S Parise, Marilda M Siqueira, Beatriz M Fortaleza, T Cristina Segatto, D Rebecca Prevots.   

Abstract

BACKGROUND: During 1998-2000, a large rubella outbreak was reported from Recife, the capital municipality of Pernambuco State, in northeastern Brazil. In 2002, a study was conducted to assess the burden of congenital rubella syndrome (CRS) after this outbreak.
METHODS: To describe the rubella outbreak, we analyzed data available from the National Notifiable Disease System. A retrospective record review for CRS was conducted at 6 maternity hospitals where 53% of Recife's resident live births occurred during 1999-2000 and 1 tertiary health care center. Suspected CRS cases were infants with any manifestation of CRS or maternal infection during pregnancy. Standard international definitions for compatible and confirmed CRS cases were used. Direct CRS costs were based on reimbursements by the National Health System.
RESULTS: From October 1998 to July 2000, Recife reported 681 confirmed rubella cases. The highest incidence of rubella was among children 5-11 years of age (5.4 per 1000 population). Forty-five suspected CRS cases were identified; 29 were clinically compatible and 2 were laboratory-confirmed. The average annual incidence of CRS was 0.9 per 1000 live births during 1999-2000. Overall costs for the first year follow-up were estimated at 61,824 US dollars in this cohort.
CONCLUSIONS: High rubella vaccination coverage is required to prevent the severe congenital disabilities and high economic costs of CRS. Increased clinician awareness is critical for early CRS detection. Complete reporting is essential to evaluate the impact of vaccination programs and to document progress toward the goal of CRS elimination in the Americas by the year 2010.

Entities:  

Mesh:

Year:  2004        PMID: 15626948

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.

Authors:  Terri B Hyde; Helena Keico Sato; LiJuan Hao; Brendan Flannery; Qi Zheng; Kathleen Wannemuehler; Flávia Helena Ciccone; Heloisa de Sousa Marques; Lily Yin Weckx; Marco Aurélio Sáfadi; Eliane de Oliveira Moraes; Marisa Mussi Pinhata; Jaime Olbrich Neto; Maria Cecilia Bevilacqua; Alfredo Tabith Junior; Tatiana Alves Monteiro; Cristina Adelaide Figueiredo; Jon K Andrus; Susan E Reef; Cristiana M Toscano; Carlos Castillo-Solorzano; Joseph P Icenogle
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

4.  Comparison of four methods using throat swabs to confirm rubella virus infection.

Authors:  Zhen Zhu; Wenbo Xu; Emily S Abernathy; Min-Hsin Chen; Qi Zheng; Tongzhan Wang; Zhenying Zhang; Congyong Li; Changyin Wang; Weikuan He; Shujie Zhou; Joseph Icenogle
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

Review 5.  Health economics of rubella: a systematic review to assess the value of rubella vaccination.

Authors:  Joseph B Babigumira; Ian Morgan; Ann Levin
Journal:  BMC Public Health       Date:  2013-04-29       Impact factor: 3.295

6.  Assessment of Economic Burden of Concurrent Measles and Rubella Outbreaks, Romania, 2011-2012.

Authors:  Joseph Njau; Denisa Janta; Aurora Stanescu; Sarah S Pallas; Adriana Pistol; Nino Khetsuriani; Susan Reef; Daniel Ciurea; Cassandra Butu; Aaron S Wallace; Laura Zimmerman
Journal:  Emerg Infect Dis       Date:  2019-06       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.